Interim BNT162b2 LP.8.1-adapted COVID-19 Vaccine Effectiveness among Non-Immunocompromised Adults ≥65 years of age in California and Louisiana, August–December 2025
Laura D. Zambrano, Tiange Yu, Jazmine Mateus, Xin Zhao, Kathleen M. Andersen, Srinivas Rao Valluri, Burcu Karakuzu İkizler, Rajeev M Nepal, Adam J. MacNeil, Hannah R. Volkman
原始摘要（英文原文）· Original abstract
Abstract Evidence on vaccine effectiveness (VE) of 2025-26 COVID-19 vaccines is limited. We estimated VE of BNT162b2 LP.8.1-adapted vaccine among non-immunocompromised adults ≥65 years through December 2025 using linked claims and immunization registry data from two U.S. states. VE against COVID-19-related ED/UC encounters was 48% (95% CI:19, 66).
Interim BNT162b2 LP.8.1-adapted COVID-19 Vaccine Effectiveness among Non-Immunocompromised Adults ≥65 years of age in California and Louisiana, August–December 2025 — 科研速览 Science Skim